Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

Human non-small cell lung cancer (NSCLC) displays activated MEK/ERK signaling due to a high frequency of K-Ras mutation and is thus a potential candidate for MEK-targeted therapy. The current study focuses on demonstrating the activity of MEK162, a MEK inhibitor under clinical testing, against NSCLC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Lett
Main Authors: Yao, Weilong, Yue, Ping, Zhang, Guojing, Owonikoko, Taofeek K., Khuri, Fadlo R., Sun, Shi-Yong
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4450809/
https://ncbi.nlm.nih.gov/pubmed/25937299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2015.04.028
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares